Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.

Abstract:

:The non-vitamin K antagonist oral anticoagulants (NOACs) are used for thromboembolic prophylaxis of patients with atrial fibrillation and in the treatment as well as secondary prophylaxis of patients with venous thromboembolism. Even though NOACs have a better safety profile than vitamin K antagonists (VKAs), there will still be bleeding complications on NOAC treatment. In some cases, stopping the NOAC and non-drug-related management such as manual compression and interventional endoscopy will be sufficient to stop the bleeding. In more serious bleeding events and before acute surgery, coagulation factor concentrates or NOAC-specific antidotes could be used. Coagulation factor concentrates can be used in patients with haemophilia and to reverse the effect of VKAs but, in NOAC-treated patients, results are inconsistent and these agents could potentially have pro-thrombotic effects. Specific antidotes for NOACs are expected to be on the market soon. Phase III clinical trials with a humanized antibody fragment directed against dabigatran (idarucizumab) and recombinant, modified factor Xa (andexanet alfa) are ongoing. A molecule (aripazine) with broad activity against various anticoagulants including NOACs is currently undergoing phase II trials. For use of these specific antidotes, it is desirable that measurements for coagulation activity with a short response delay are widely available for the different NOACs and further research in this field is needed. Furthermore, guidelines for antidote use, including general measures for the treatment of NOAC-related bleeding, should be available.

journal_name

Drug Saf

journal_title

Drug safety

authors

Husted S,Verheugt FW,Comuth WJ

doi

10.1007/s40264-015-0357-x

subject

Has Abstract

pub_date

2016-01-01 00:00:00

pages

5-13

issue

1

eissn

0114-5916

issn

1179-1942

pii

10.1007/s40264-015-0357-x

journal_volume

39

pub_type

杂志文章,评审
  • Association between leukotriene-modifying agents and suicide: what is the evidence?

    abstract::The US FDA has issued safety alerts and required manufacturers of leukotriene-modifying agents (LTMAs), including montelukast, zafirlukast and zileuton, to include suicide and neuropsychiatric events as a precaution in the drug label. This paper reviews the existing evidence on the potential association between the LT...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11587260-000000000-00000

    authors: Schumock GT,Lee TA,Joo MJ,Valuck RJ,Stayner LT,Gibbons RD

    更新日期:2011-07-01 00:00:00

  • Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.

    abstract:BACKGROUND:Newly approved drugs, in comparison with older drugs, are more often prescribed to patients who have not responded satisfactorily to established related drugs or as first-line therapy to patients with a high baseline risk for adverse outcomes (i.e. channelling). However, these patients are less likely to ben...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200831020-00004

    authors: Layton D,Souverein PC,Heerdink ER,Shakir SA,Egberts AC

    更新日期:2008-01-01 00:00:00

  • Treating breast cancer during pregnancy. What can be taken safely?

    abstract::The occurrence of breast cancer during pregnancy is a rare clinical situation. However, if it is diagnosed, a multidisciplinary approach involving an obstetrician, a medical oncologist and a surgeon is needed. In this situation, breast cancer should be treated according to the same principles applied in nonpregnant pa...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199818020-00005

    authors: Espié M,Cuvier C

    更新日期:1998-02-01 00:00:00

  • Effect of drug treatment on quality of life in mild to moderate heart failure.

    abstract::The most frequently reported symptoms in heart failure are fatigue and dyspnoea, which limit exercise tolerance. However, several surveys reveal other changes in physical and psychological well-being which affect the patient's perception of 'quality of life'. The introduction of new treatments for heart failure has st...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199106040-00002

    authors: Waller DG

    更新日期:1991-07-01 00:00:00

  • Drug-induced endocrine and metabolic disorders.

    abstract::Complex interactions exist amongst the various components of the neuroendocrine system in order to maintain homeostasis, energy balance and reproductive function. These components include the hypothalamus-pituitary- adrenal and -gonadal axes, the renin-angiotensin-aldosterone system, the sympathetic nervous system and...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200730030-00005

    authors: Ma RC,Kong AP,Chan N,Tong PC,Chan JC

    更新日期:2007-01-01 00:00:00

  • What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?

    abstract::In the US, adverse drug reactions (ADRs) rank between the fourth to sixth leading cause of death, ahead of pneumonia and diabetes mellitus. An important reason for the high incidence of serious and fatal ADRs is that the existing drug development paradigms do not generate adequate information on the mechanistic source...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200124020-00001

    authors: Ozdemir V,Shear NH,Kalow W

    更新日期:2001-01-01 00:00:00

  • A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience.

    abstract::Zopiclone is a cyclopyrrolone hypnosedative that is chemically unrelated to the benzodiazepines but nevertheless potentiates gamma-aminobutyric acid-mediated neuronal inhibition, and has demonstrated proven efficacy and good tolerability in the treatment of insomnia over 15 years of use. Zopiclone is indicated for sho...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199921060-00003

    authors: Hajak G

    更新日期:1999-12-01 00:00:00

  • Benefit-risk assessment of zaleplon in the treatment of insomnia.

    abstract::Insomnia is a heterogeneous, highly prevalent condition that is associated with a high level of psychiatric, physical, social and economic morbidity. The treatment of insomnia involves pharmacological and non-pharmacological interventions. The mainstay of pharmacological treatment of insomnia has been the benzodiazepi...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200528040-00003

    authors: Barbera J,Shapiro C

    更新日期:2005-01-01 00:00:00

  • Enabling Data-Driven Clinical Quality Assurance: Predicting Adverse Event Reporting in Clinical Trials Using Machine Learning.

    abstract:INTRODUCTION:Adverse event (AE) under-reporting has been a recurrent issue raised during health authorities Good Clinical Practices (GCP) inspections and audits. Moreover, safety under-reporting poses a risk to patient safety and data integrity. The current clinical Quality Assurance (QA) practices used to detect AE un...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00831-4

    authors: Ménard T,Barmaz Y,Koneswarakantha B,Bowling R,Popko L

    更新日期:2019-09-01 00:00:00

  • Evaluation of Use of Technologies to Facilitate Medical Chart Review.

    abstract:INTRODUCTION:While medical chart review remains the gold standard to validate health conditions or events identified in administrative claims and electronic health record databases, it is time consuming, expensive and can involve subjective decisions. AIM:The aim of this study was to describe the landscape of technolo...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00838-x

    authors: Straub L,Gagne JJ,Maro JC,Nguyen MD,Beaulieu N,Brown JS,Kennedy A,Johnson M,Wright A,Zhou L,Wang SV

    更新日期:2019-09-01 00:00:00

  • Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia.

    abstract::The purpose of this review is to assess the benefits and risks associated with the use of the ketolide antibacterial telithromycin, currently licensed for the treatment of adults with mild to moderate community-acquired pneumonia (CAP). Telithromycin is active against both the major (Streptococcus pneumoniae, Haemophi...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200831070-00002

    authors: Brown SD

    更新日期:2008-01-01 00:00:00

  • Management options for cancer therapy-related anaemia.

    abstract::Anaemia is common in patients with haematological malignancy, occurring in the majority of patients with malignant disease who are treated with chemotherapy. Most patients will have their anaemia attributed to the cytokine-mediated anaemia of chronic disease. Many of these patients with anaemia will be symptomatic wit...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200225070-00006

    authors: Littlewood TJ

    更新日期:2002-01-01 00:00:00

  • Drug-Induced Mitochondrial Toxicity.

    abstract::The mitochondrial respiratory chain (MRC) and ATP synthase (complex V) play an essential role in cellular energy production by the process of oxidative phosphorylation. In addition to inborn errors of metabolism, as well as secondary causes from disease pathophysiology, an impairment of oxidative phosphorylation can r...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-016-0417-x

    authors: Hargreaves IP,Al Shahrani M,Wainwright L,Heales SJ

    更新日期:2016-07-01 00:00:00

  • Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study.

    abstract:INTRODUCTION:Controversy exists about an association between angiotensin-converting-enzyme inhibitors (ACEIs), angiotensin-receptor blockers (ARBs), and thiazides (TZs) and the risk of malignant melanoma (MM), and non-melanoma skin cancer-basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). OBJECTIVE:The aim ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-016-0487-9

    authors: Nardone B,Majewski S,Kim AS,Kiguradze T,Martinez-Escala EM,Friedland R,Amin A,Laumann AE,Edwards BJ,Rademaker AW,Martini MC,West DP

    更新日期:2017-03-01 00:00:00

  • Dopamine Agonists and Impulse Control Disorders: A Complex Association.

    abstract::Impulse control disorders (ICDs) are a well-known adverse effect of dopamine agonists (DAAs). This critical review aims to summarize data on the prevalence and factors associated with the development of an ICD simultaneous to DAA use. A search of two electronic databases was completed from inception to July 2017. The ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-017-0590-6

    authors: Grall-Bronnec M,Victorri-Vigneau C,Donnio Y,Leboucher J,Rousselet M,Thiabaud E,Zreika N,Derkinderen P,Challet-Bouju G

    更新日期:2018-01-01 00:00:00

  • Unintended Effects of Communicating About Drug Safety Issues: A Critical Review of the Literature.

    abstract::Communications about the safety and effectiveness of human drugs can influence patients' and prescribers' perceptions and behaviors, which in turn can affect the public's health more broadly. We conducted a critical review of the literature on the unintended effects from communicating information to the public about s...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-019-00840-3

    authors: DeFrank JT,McCormack L,West SL,Lefebvre C,Burrus O

    更新日期:2019-10-01 00:00:00

  • Using MedDRA: implications for risk management.

    abstract::The introduction of MedDRA, the Medical Dictionary for Regulatory Activities, as a standardised terminology may have a major impact on the performance of risk management. Thus, MedDRA is likely to have an important effect on the analysis of clinical trial safety data. Review of the most commonly used terms in clinical...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200427080-00010

    authors: Brown EG

    更新日期:2004-01-01 00:00:00

  • Measles vaccination and inflammatory bowel disease: controversy laid to rest?

    abstract::The increasing incidence of Crohn's disease has lead to speculation about changes in exposures to environmental or infectious agents. Considerable attention has focused on the role of measles infection and/or vaccination in the pathogenesis of Crohn's disease and ulcerative colitis. Current evidence regarding the asso...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200124130-00001

    authors: Davis RL,Bohlke K

    更新日期:2001-01-01 00:00:00

  • Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data.

    abstract:OBJECTIVE:Minocycline is an antibacterial drug used in the treatment of acne. Concern has been expressed over the possibility of severe adverse reactions to minocycline, including hepatitis. This study set out to identify and characterise reported cases of hepatotoxicity associated with the use of minocycline. METHODS...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200023040-00006

    authors: Lawrenson RA,Seaman HE,Sundström A,Williams TJ,Farmer RD

    更新日期:2000-10-01 00:00:00

  • Improving follow-up rates in spontaneous adverse drug reaction reporting: effectiveness of a targeted letter used by a regional centre in the UK.

    abstract:BACKGROUND:Spontaneous reports of suspected adverse drug reactions to regulatory bodies and market authorization holders are important in pharmacovigilance. Follow-up information, which can be difficult to obtain, is often required from reporters; therefore, we developed targeted follow-up letters that we hoped would m...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11318940-000000000-00000

    authors: Anton C,Cox AR,Ferner RE

    更新日期:2009-01-01 00:00:00

  • Erice Call for Change: Utilising Patient Experiences to Enhance the Quality and Safety of Healthcare.

    abstract::This 'Erice Call for Change' is a report from a group of experts, patients and patient representatives who met in Erice in September 2019 following previous similar meetings after the original Erice Declaration (1996). The aim of the meeting was to discuss the challenge of causal complexity and individual variation in...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-020-00919-2

    authors: Rocca E,Anjum RL

    更新日期:2020-06-01 00:00:00

  • Signal generation in the New Zealand Intensive Medicines Monitoring Programme: a combined clinical and statistical approach.

    abstract::The New Zealand Intensive Medicines Monitoring Programme (IMMP) undertakes prospective observational cohort studies on selected new drugs in the early postmarketing period using prescription-event monitoring (PEM) methodology with the purpose of identifying signals of previously unrecognised ADRs and establishing risk...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200225060-00007

    authors: Coulter DM

    更新日期:2002-01-01 00:00:00

  • Effect of Medications for Gastric Acid-Related Symptoms on Total Motile Sperm Count and Concentration: A Case-Control Study in Men of Subfertile Couples from the Netherlands.

    abstract:INTRODUCTION:Gastric acid-related symptoms are highly prevalent in the general population (21-40%), and more than 11% of individuals use medication for the treatment of these symptoms. The uptake of micronutrients is dependent on the gastrointestinal potential of hydrogen (pH). OBJECTIVE:We hypothesized that medicatio...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-016-0488-8

    authors: Huijgen NA,Goijen HJ,Twigt JM,Mulders AG,Lindemans J,Dohle GR,Laven JS,Steegers-Theunissen RP

    更新日期:2017-03-01 00:00:00

  • Safety of clopidogrel and aspirin for stroke prevention: implications of the CHARISMA trial.

    abstract::Antiplatelet therapy is universally recommended for the prevention of recurrent events in patients with noncardioembolic ischaemic stroke or transient ischaemic attack (TIA), acute and chronic coronary artery disease, or peripheral arterial disease. However, choosing which antiplatelet agents to use in these situation...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200831060-00001

    authors: Ruland S

    更新日期:2008-01-01 00:00:00

  • Managing Risks with Immune Therapies in Multiple Sclerosis.

    abstract::Since the introduction of the interferons in the 1990s, a multitude of different immunomodulatory and immunosuppressant disease-modifying therapies for multiple sclerosis (MS) have been developed. They have all shown positive effects on clinical endpoints such as relapse rate and disease progression and are a heteroge...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-018-0782-8

    authors: Förster M,Küry P,Aktas O,Warnke C,Havla J,Hohlfeld R,Mares J,Hartung HP,Kremer D

    更新日期:2019-05-01 00:00:00

  • Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China.

    abstract:INTRODUCTION:Electronic healthcare databases (EHDs) are used increasingly for post-marketing drug safety surveillance and pharmacoepidemiology in Europe and North America. However, few studies have examined the potential of these data sources in China. METHODS:Three major types of EHDs in China (i.e., a regional commu...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-017-0589-z

    authors: Yang Y,Zhou X,Gao S,Lin H,Xie Y,Feng Y,Huang K,Zhan S

    更新日期:2018-01-01 00:00:00

  • Drug therapy and the older person: role of the pharmacist.

    abstract::Older people in the UK receive a disproportionate amount of medication. They comprise 18% of the population but receive 45% of all prescription items. Not surprisingly they experience drug-related illnesses - in 1980, 1 in 10 admissions to acute geriatric units were wholly or partly due to adverse drug reactions. Drug...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199819040-00001

    authors: Denham MJ,Barnett NL

    更新日期:1998-10-01 00:00:00

  • Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions.

    abstract:INTRODUCTION:Adverse drug reactions (ADRs) are unintended reactions caused by a drug or combination of drugs taken by a patient. The current safety surveillance system relies on spontaneous reporting systems (SRSs) and more recently on observational health data; however, ADR detection may be delayed and lack geographic...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-020-00943-2

    authors: Li Y,Jimeno Yepes A,Xiao C

    更新日期:2020-09-01 00:00:00

  • Monoamine oxidase inhibitors. An update on drug interactions.

    abstract::After initial enthusiasm, the use of monoamine oxidase inhibitors (MAOIs) has been limited by the wide range of MAOI-drug and MAOI-food interactions that are possible, particularly with sympathomimetic medications or tyramine-containing foods, resulting in hypertensive reactions. Despite their clinical benefits, this ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199614040-00002

    authors: Livingston MG,Livingston HM

    更新日期:1996-04-01 00:00:00

  • Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.

    abstract:BACKGROUND:Following reports of sudden death in patients taking medication to treat attention-deficit hyperactivity disorder (ADHD), this study aimed to identify cases of death in patients prescribed stimulants and atomoxetine and to determine any association between these and sudden death. METHOD:The UK General Pract...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11317630-000000000-00000

    authors: McCarthy S,Cranswick N,Potts L,Taylor E,Wong IC

    更新日期:2009-01-01 00:00:00